futmedМедицина будущегоThe Future of Medicine3033-90573033-9669Ленинградская областная клиническая больница10.67666/3033-9057-2026-1-1-45-54futmed-60Research ArticleОнкология, лучевая терапияTumor budding — независимый прогностический фактор колоректального ракаTumor budding — independent predictor factor of colorectal cancerhttps://orcid.org/0000-0002-0695-3625ПоповМ. А.PopovMaxim A.

Попов Максим Андреевич — врач-онколог, 

194291, г. Санкт- Петербург, пр. Луначарского, д. 45а.

Maxim A. Popov — Oncologist, 

45, bldg. 1, liter A Lunacharsky ave., Saint Petersburg, 194291.

123456@mail.ruhttps://orcid.org/0009-0004-5312-934XСавчукС. А.SavchukSergey A.

Савчук Сергей Андреевич — врач-онколог, 

194291, г. Санкт- Петербург, пр. Луначарского, д. 45а.

Sergey A. Savchuk — Oncologist, 

45, bldg. 1, liter A Lunacharsky ave., Saint Petersburg, 194291.

savchuk-sergej@mail.ruhttps://orcid.org/0000-0002-5526-1385КовтунД. П.KovtunDemyan P.

Ковтун Демьян Павлович — кандидат медицинских наук, заведующий Центральным патолого-анатомическим отделением общей патологии; доцент кафедры патологической анатомии с курсом судебной медицины им. профессора Д.Д. Лохова, 

194291, Санкт- Петербург, ул. Сантьяго-де- Куба, д. 7;

194100, г. Санкт- Петербург, ул. Литовская, д. 2.

Demyan P. Kovtun — Cand. Sci. (Medicine), Head of the Central Pathological and Anatomical Department of General Pathology; Associate Professor of the Department of Pathological Anatomy with a course in Forensic Medicine named after Professor D.D. Lokhov,

7, Santiago de Cuba str., St. Petersburg,194291;

2, Litovskaya str., St. Petersburg,194100.

damian85@mail.ruhttps://orcid.org/0000-0002-0249-4759ХрыковГ. Н.KhrykovGleb N.

Хрыков Глеб Николаевич — доктор медицинских наук, профессор кафедры онкологии, лучевой терапии и радиологии им. проф. Н.Е. Яхонтова; руководитель 3-го стационара,

г. Нижний Новгород.

Gleb N. Khrykov — Dr. Sci. (Medicine), Professor at the Department of Oncology, Radiation Therapy and Radiology named after Prof. N.E. Yakhontov; Head of the 3rd Inpatient Facility,

Nizhny Novgorod.

123456@mail.ruГБУЗ «Ленинградская областная клиническая больница»РоссияLeningrad Regional Clinical HospitalRussian FederationГКУЗ Ленинградской области «Бюро судебно-медицинской экспертизы»; ФГБОУ ВО «Санкт- Петербургский государственный педиатрический медицинский университет» Минздрава РоссииРоссияLeningrad Regional Pathological Anatomy Bureau; St. Petersburg State Pediatric Medical UniversityRussian FederationПоволжский исследовательский медицинский университет; ГАУЗ НО «Научно-исследовательский институт клинической онкологии «Нижегородский областной клинический онкологический диспансер»РоссияVolga Research Medical University; Nizhny Novgorod Regional Clinical Oncology Dispensary, Research Institute of Clinical OncologyRussian Federation202614082026114554Copyright © Попов М.А., Савчук С.А., Ковтун Д.П., Хрыков Г.Н., 20262026Попов М.А., Савчук С.А., Ковтун Д.П., Хрыков Г.Н.Popov M.A., Savchuk S.A., Kovtun D.P., Khrykov G.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://futmed.elpub.ru/jour/article/view/60

В последние годы пристальное внимание исследователей приковано к изучению канцерогенеза и дифференцировки опухолей колоректального рака (КРР). Механизмы возникновения и агрессивности течения заболевания получают все большую аргументацию. Понимание биологии опухолевого роста вносит свои изменения в систему лечения пациентов с КРР. В основу представления о разнородности фенотипов опухоли были положены современные молекулярные и патоморфологические методы диагностики.

In last years, the attention of researchers is focused on the study of carcinogenesis and differentiation tumors of colorectal cancer (CRC). Mechanisms of the onset and aggressiveness of the disease are gaining more and more arguments. The biology of tumor becomes more understandable and introduces its changes into the system of treatment of patients with CRC. The heterogeneity of tumor phenotypes was based on modern molecular and pathomorphological methods of diagnosis.

колоректальный ракtumor buddingметастазы в лимфатические узлыпрогностические факторыпатоморфологическое исследованиеITBCCcolorectal cancertumor buddinglymph node metastasesprognostic factorspathological examinationITBCCReferencesNagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020 Jan;76(2):182-188. doi: 10.1111/his.13975. Epub 2019 Nov 13. PMID: 31433515; PMCID: PMC7003895.Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020 Jan;76(2):182-188. doi: 10.1111/his.13975. Epub 2019 Nov 13. PMID: 31433515; PMCID: PMC7003895.Zlobec I., Lugli A., Baker K., et al. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumor budding in colorectal cancer. Journal Pathology. 2007; 212: 260–268. https://dx.doi.org/10.3748%2Fwjg.v16.i38.4823Zlobec I., Lugli A., Baker K., et al. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumor budding in colorectal cancer. Journal Pathology. 2007; 212: 260–268. https://dx.doi.org/10.3748%2Fwjg.v16.i38.4823Ueno H., Mochizuki H., Hashiguchi Y., et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004; 127:385–394. https://doi.org/10.1053/j.gastro.2004.04.022Ueno H., Mochizuki H., Hashiguchi Y., et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004; 127:385–394. https://doi.org/10.1053/j.gastro.2004.04.022Ueno H., Murphy J., Jass J.R., et al. Tumor 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002; 40:127–132. https://doi.org/10.1046/j.1365-2559.2002.01324.xUeno H., Murphy J., Jass J.R., et al. Tumor 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002; 40:127–132. https://doi.org/10.1046/j.1365-2559.2002.01324.xMitrovic B., Schaeffer D.F., Riddell R.H., et al. Tumor budding in colorectal carcinoma: time to take notice. Modern Pathology. 2012; 25:1315–1325. https://doi.org/10.1038/modpathol.2012.94Mitrovic B., Schaeffer D.F., Riddell R.H., et al. Tumor budding in colorectal carcinoma: time to take notice. Modern Pathology. 2012; 25:1315–1325. https://doi.org/10.1038/modpathol.2012.94Kajiwara Y., Ueno H., Hashiguchi Y., et al. Risk factors of nodal involvement in T2 colorectal cancer. Diseases of the Colon and Rectum. 2010; 53:1393–1399. https://doi.org/10.1007/DCR.0b013e3181ec5f66Kajiwara Y., Ueno H., Hashiguchi Y., et al. Risk factors of nodal involvement in T2 colorectal cancer. Diseases of the Colon and Rectum. 2010; 53:1393–1399. https://doi.org/10.1007/DCR.0b013e3181ec5f66De Smedt L., Palmans S., Sagaert X., Tumor budding in colorectal cancer: What do we know and what can we do? Virchows Archiv. 2016; 468:397–408. https://doi.org/10.1007/s00428-015-1886-5De Smedt L., Palmans S., Sagaert X., Tumor budding in colorectal cancer: What do we know and what can we do? Virchows Archiv. 2016; 468:397–408. https://doi.org/10.1007/s00428-015-1886-5Van Wyk H.C., Park J., Roxburgh C., et al. The role of tumor budding in predicting survival in patients with primary operable colorectal cancer: A systematic review. Cancer Treatment Reviews. 2015; 41:151–159. https://doi.org/10.1016/j.ctrv.2014.12.007Van Wyk H.C., Park J., Roxburgh C., et al. The role of tumor budding in predicting survival in patients with primary operable colorectal cancer: A systematic review. Cancer Treatment Reviews. 2015; 41:151–159. https://doi.org/10.1016/j.ctrv.2014.12.007Rogers A.C., Winter D.C., Heeney A., et al. Systematic review and meta-analysis of the impact of tumor budding in colorectal cancer. British Journal of Cancer. 2016; 115:831–840. https://doi.org/10.1038/bjc.2016.274Rogers A.C., Winter D.C., Heeney A., et al. Systematic review and meta-analysis of the impact of tumor budding in colorectal cancer. British Journal of Cancer. 2016; 115:831–840. https://doi.org/10.1038/bjc.2016.274Imai T. Growth patterns in human carcinoma. Their classification and relation to prognosis. Obstetrics and Gynecology. 1960; 16:296–308.Imai T. Growth patterns in human carcinoma. Their classification and relation to prognosis. Obstetrics and Gynecology. 1960; 16:296–308.Hase K., Shatney C., Johnso, D., et al. Prognostic value of tumor “budding” in patients with colorectal cancer. Diseases of the Colon and Rectum. 1993; 36:627–635.Hase K., Shatney C., Johnso, D., et al. Prognostic value of tumor “budding” in patients with colorectal cancer. Diseases of the Colon and Rectum. 1993; 36:627–635.Morodomi T., Isomoto H., Shirouzu K., et al. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer. 1989; 63:539–543.Morodomi T., Isomoto H., Shirouzu K., et al. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer. 1989; 63:539–543.Gurzu S., Turdean S., Kovecsi A., et al. Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update. World Journal Clinical Cases. 2015; 3:393-404. https://dx.doi.org/10.12998%2Fwjcc.v3.i5.393Gurzu S., Turdean S., Kovecsi A., et al. Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update. World Journal Clinical Cases. 2015; 3:393-404. https://dx.doi.org/10.12998%2Fwjcc.v3.i5.393Hay E.D. An overview of epithelio-mesenchymal transformation. Acta Anatomica (Basel). 1995; 154:8-20.Hay E.D. An overview of epithelio-mesenchymal transformation. Acta Anatomica (Basel). 1995; 154:8-20.Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation. 2009; 119:1420-1428. https://doi.org/10.1172/JCI39104Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation. 2009; 119:1420-1428. https://doi.org/10.1172/JCI39104Kraus S., Vay C., Baldus S. et al. Expression of wingless-type mouse mammary tumor virus integration site family pathway effectors in lymphatic and hepatic metastases of patients with colorectal cancer: Associations with the primary tumor. Oncology Letters. 2015; 10:863-868. https://doi.org/10.3892/ol.2015.3291Kraus S., Vay C., Baldus S. et al. Expression of wingless-type mouse mammary tumor virus integration site family pathway effectors in lymphatic and hepatic metastases of patients with colorectal cancer: Associations with the primary tumor. Oncology Letters. 2015; 10:863-868. https://doi.org/10.3892/ol.2015.3291Zlobec I., Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1:651–661. https://dx.doi.org/10.18632%2Foncotarget.199Zlobec I., Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1:651–661. https://dx.doi.org/10.18632%2Foncotarget.199Beaton C., Twine C.P., Williams G.L., Radcliffe AG. Systematic review and meta-analysis of histopathological factors influencing the risk of lymphnode metastasis in early colorectal cancer. Colorectal Disease. 2013; 15:788-97. https://doi.org/10.1111/codi.12129Beaton C., Twine C.P., Williams G.L., Radcliffe AG. Systematic review and meta-analysis of histopathological factors influencing the risk of lymphnode metastasis in early colorectal cancer. Colorectal Disease. 2013; 15:788-97. https://doi.org/10.1111/codi.12129Coverlizza S., Risio M., Ferrari A., et al. Colorectal adenomas containing invasive carcinoma. Pathologic assessment of lymph node metastatic potential. Cancer. 1989; 64: 1937-1947.Coverlizza S., Risio M., Ferrari A., et al. Colorectal adenomas containing invasive carcinoma. Pathologic assessment of lymph node metastatic potential. Cancer. 1989; 64: 1937-1947.Ueno H., Hase K., Hashiguchi Y., et al. Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review. Journal Gastroenterology. 2014; 49:1314. https://doi.org/10.1007/s00535-013-0881-3Ueno H., Hase K., Hashiguchi Y., et al. Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review. Journal Gastroenterology. 2014; 49:1314. https://doi.org/10.1007/s00535-013-0881-3Bosch S., Teerenstra S., De Wilt J.W., et al. Predicting lymph node metastasis in pT1 colorectal cancer: A systematic review of risk factors providing rationale for therapy decisions. Endoscopy. 2013; 45(10):827-834 https://doi.org/10.1055/s-0033-1344238Bosch S., Teerenstra S., De Wilt J.W., et al. Predicting lymph node metastasis in pT1 colorectal cancer: A systematic review of risk factors providing rationale for therapy decisions. Endoscopy. 2013; 45(10):827-834 https://doi.org/10.1055/s-0033-1344238Vieth M., Quirke P., Lambert R., et al. International Agency for Research on Cancer. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition— annotations of colorectal lesions. Endoscopy. 2012; 44(3):131-139. https://doi.org/10.1055/s-0032-1309797Vieth M., Quirke P., Lambert R., et al. International Agency for Research on Cancer. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition— annotations of colorectal lesions. Endoscopy. 2012; 44(3):131-139. https://doi.org/10.1055/s-0032-1309797Hari D.M., Leung A.M., Lee J.H., et al. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? Journal of the American College of Surgeons. 2013; 217(2):181-190. https://doi.org/10.1016/j.jamcollsurg.2013.04.018Hari D.M., Leung A.M., Lee J.H., et al. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? Journal of the American College of Surgeons. 2013; 217(2):181-190. https://doi.org/10.1016/j.jamcollsurg.2013.04.018Benson A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. Journal of Clinical Oncology. 2004; 22:3408-3419. https://doi.org/10.1200/JCO.2004.05.063Benson A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. Journal of Clinical Oncology. 2004; 22:3408-3419. https://doi.org/10.1200/JCO.2004.05.063Gill S., Loprinzi C.L., Sargent D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? Journal of Clinical Oncology. 2004; 22:1797-1806. https://doi.org/10.1200/JCO.2004.09.059Gill S., Loprinzi C.L., Sargent D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? Journal of Clinical Oncology. 2004; 22:1797-1806. https://doi.org/10.1200/JCO.2004.09.059Benson A.B., Venook A.P., Grothey A., et al. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2018. Journal National Comprehensive Cancer Network (JNCCN). 2018; 16(4):359-369 https://doi.org/10.6004/jnccn.2018.0021Benson A.B., Venook A.P., Grothey A., et al. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2018. Journal National Comprehensive Cancer Network (JNCCN). 2018; 16(4):359-369 https://doi.org/10.6004/jnccn.2018.0021Nakamura T., Mitomi H., Kanazawa H., et al. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Diseases of the Colon and Rectum. 2008; 51:568-572. https://doi.org/10.1007/s10350-008-9192-9Nakamura T., Mitomi H., Kanazawa H., et al. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Diseases of the Colon and Rectum. 2008; 51:568-572. https://doi.org/10.1007/s10350-008-9192-9Lai Y.H., Wu L.C., Li P.S., et al. Tumor budding is a reproducible index for risk stratification of patients with stage II colon cancer. Colorectal Disease. 2014; 16:259-264. https://doi.org/10.1111/codi.12454Lai Y.H., Wu L.C., Li P.S., et al. Tumor budding is a reproducible index for risk stratification of patients with stage II colon cancer. Colorectal Disease. 2014; 16:259-264. https://doi.org/10.1111/codi.12454Tanaka M., Hashiguchi Y., Ueno H., et al. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Diseases of the Colon and Rectum. 2003; 46:1054-1059. https://doi.org/10.1007/s10350-004-7280-zTanaka M., Hashiguchi Y., Ueno H., et al. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Diseases of the Colon and Rectum. 2003; 46:1054-1059. https://doi.org/10.1007/s10350-004-7280-zWang L.M., Kevans D., Mulcahy H., et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. The American Journal of Surgical Pathology. 2009; 33:134-141. https://doi.org/10.1097/PAS.0b013e318184cd55Wang L.M., Kevans D., Mulcahy H., et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. The American Journal of Surgical Pathology. 2009; 33:134-141. https://doi.org/10.1097/PAS.0b013e318184cd55Betge J., Kornprat P., Pollheimer M.J., et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Annals of Surgical Oncology. 2012; 19:3706-3712. https://doi.org/10.1245/s10434-012-2426-zBetge J., Kornprat P., Pollheimer M.J., et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Annals of Surgical Oncology. 2012; 19:3706-3712. https://doi.org/10.1245/s10434-012-2426-zCanney A.L., Kevans D., Wang L.M., et al. Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumor budding. Histopathology. 2012; 61:488-496. https://doi.org/10.1111/j.1365-2559.2012.04250.xCanney A.L., Kevans D., Wang L.M., et al. Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumor budding. Histopathology. 2012; 61:488-496. https://doi.org/10.1111/j.1365-2559.2012.04250.xHorcic M., Koelzer V.H., Karamitopoulou E., et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Human Pathology. 2013; 44:697-705. https://doi.org/10.1016/j.humpath.2012.07.026Horcic M., Koelzer V.H., Karamitopoulou E., et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Human Pathology. 2013; 44:697-705. https://doi.org/10.1016/j.humpath.2012.07.026Schmoll H.J., Van Cutsem E., Stein A., et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals Oncology. 2012; 23:2479-516 https://doi.org/10.1093/annonc/mds236Schmoll H.J., Van Cutsem E., Stein A., et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals Oncology. 2012; 23:2479-516 https://doi.org/10.1093/annonc/mds236Rogers A.C., Gibbons D., Hanly A.M., et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Modern Pathology. 2014; 27:156-162. https://doi.org/10.1038/modpathol.2013.124Rogers A.C., Gibbons D., Hanly A.M., et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Modern Pathology. 2014; 27:156-162. https://doi.org/10.1038/modpathol.2013.124Zlobec I., Hadrich M., Dawson H., et al. Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. British Journal of Cancer. 2014; 110:1008-1013. https://dx.doi.org/10.1038%2Fbjc.2013.797Zlobec I., Hadrich M., Dawson H., et al. Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. British Journal of Cancer. 2014; 110:1008-1013. https://dx.doi.org/10.1038%2Fbjc.2013.797Giger O.T., Comtesse S.C., Lugli A., et al. Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Modern Pathology. 2012; 25:1048-1053. https://doi.org/10.1038/modpathol.2012.56Giger O.T., Comtesse S.C., Lugli A., et al. Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Modern Pathology. 2012; 25:1048-1053. https://doi.org/10.1038/modpathol.2012.56Lugli A., Kirsch R., Ajioka Y. et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern Pathology. 2017; 30(9):1299-1311 https://doi.org/10.1038/modpathol.2017.46Lugli A., Kirsch R., Ajioka Y. et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern Pathology. 2017; 30(9):1299-1311 https://doi.org/10.1038/modpathol.2017.46Ueno H., Kajiwara Y., Shimazaki H., et al. New criteria for histologic grading of colorectal cancer. The American Journal of Surgical Pathology. 2012; 36:193-201. https://doi.org/10.1097/PAS.0b013e318235edeeUeno H., Kajiwara Y., Shimazaki H., et al. New criteria for histologic grading of colorectal cancer. The American Journal of Surgical Pathology. 2012; 36:193-201. https://doi.org/10.1097/PAS.0b013e318235edeeBarresi V., Branca G., Ieni A., et al. Poorly differentiated clusters (PDCs) as a novel histological predictor of nodal metastases in pT1 colorectal cancer. Virchows Archiv. 2014; 464:655-662. https://doi.org/10.1007/s00428-014-1580-zBarresi V., Branca G., Ieni A., et al. Poorly differentiated clusters (PDCs) as a novel histological predictor of nodal metastases in pT1 colorectal cancer. Virchows Archiv. 2014; 464:655-662. https://doi.org/10.1007/s00428-014-1580-zKawachi H., Eishi Y., Ueno H., et al. A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study. Modern Pathology. 2015; 28:872-879. https://doi.org/10.1038/modpathol.2015.36Kawachi H., Eishi Y., Ueno H., et al. A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study. Modern Pathology. 2015; 28:872-879. https://doi.org/10.1038/modpathol.2015.36Wada H., Shiozawa M., Katayama K., et al. Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer. Journal of Gastroenterology. 2015; 50:727–734. https://doi.org/10.1007/s00535-015-1057-0Wada H., Shiozawa M., Katayama K., et al. Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer. Journal of Gastroenterology. 2015; 50:727–734. https://doi.org/10.1007/s00535-015-1057-0Kitajima K., Fujimori T., Fujii S., et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. Journal of Gastroenterology. 2004; 39:534–543. https://doi.org/10.1007/s00535-004-1339-4Kitajima K., Fujimori T., Fujii S., et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. Journal of Gastroenterology. 2004; 39:534–543. https://doi.org/10.1007/s00535-004-1339-4Keum M.A., Lim S.B., Kim S.A., et al. Clinicopathologic factors affecting recurrence after curative surgery for stage I colorectal cancer. Journal of Korean Society of Coloproctology. 2012; 28:49–55. https://dx.doi.org/10.3393%2Fjksc.2012.28.1.49Keum M.A., Lim S.B., Kim S.A., et al. Clinicopathologic factors affecting recurrence after curative surgery for stage I colorectal cancer. Journal of Korean Society of Coloproctology. 2012; 28:49–55. https://dx.doi.org/10.3393%2Fjksc.2012.28.1.49Tateishi Y., Nakanishi Y., Taniguchi H., et al. Pathological prognostic factors predicting lymph node metastasis in submucosal invasive (T1) colorectal carcinoma. Modern Pathology. 2010; 23:1068–1072. https://doi.org/10.1038/modpathol.2010.88Tateishi Y., Nakanishi Y., Taniguchi H., et al. Pathological prognostic factors predicting lymph node metastasis in submucosal invasive (T1) colorectal carcinoma. Modern Pathology. 2010; 23:1068–1072. https://doi.org/10.1038/modpathol.2010.88Van de Velde C.J., Aristei C., Boelens P.G., et al. EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. European Journal of Cancer. 2013; 49:2784–2790. https://doi.org/10.1016/j.ejca.2013.04.032Van de Velde C.J., Aristei C., Boelens P.G., et al. EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. European Journal of Cancer. 2013; 49:2784–2790. https://doi.org/10.1016/j.ejca.2013.04.032Quirke P., West N.P., Nagtegaal I.D. EURECCA consensus conference highlights about colorectal cancer clinical management: the pathologists expert review. Virchows Archiv. 2014; 464:129–134. http://doi.org/10.1007/s00428-013-1534-xQuirke P., West N.P., Nagtegaal I.D. EURECCA consensus conference highlights about colorectal cancer clinical management: the pathologists expert review. Virchows Archiv. 2014; 464:129–134. http://doi.org/10.1007/s00428-013-1534-xVan de Velde C.J., Boelens P.G., Borras J.M., et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. European Journal of Cancer. 2014; 49(13):2784-2790. https://doi.org/10.1016/j.ejca.2013.04.032Van de Velde C.J., Boelens P.G., Borras J.M., et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. European Journal of Cancer. 2014; 49(13):2784-2790. https://doi.org/10.1016/j.ejca.2013.04.032Hayes B.D., Maguire A., Conlon N., et al. Reproducibility of the rapid bud count method for assessment of tumor budding in stage II colorectal cancer. The American Journal of Surgical Pathology. 2010; 34:746–748. https://doi.org/10.1097/PAS.0b013e3181da76b6Hayes B.D., Maguire A., Conlon N., et al. Reproducibility of the rapid bud count method for assessment of tumor budding in stage II colorectal cancer. The American Journal of Surgical Pathology. 2010; 34:746–748. https://doi.org/10.1097/PAS.0b013e3181da76b6Pritchard C.C., Grady W.M. Colorectal cancer molecular biology moves into clinical practice. Gut 2011; 60:116–129. http://doi.org/10.1136/gut.2009.206250Pritchard C.C., Grady W.M. Colorectal cancer molecular biology moves into clinical practice. Gut 2011; 60:116–129. http://doi.org/10.1136/gut.2009.206250Max N., Harbaum L., Pollheimer M.J., et al. Tumor budding with and without admixed inflammation: two different sides of the same coin? British Journal of Cancer. 2016; 114: 368–371. https://dx.doi.org/10.1038%2Fbjc.2015.454Max N., Harbaum L., Pollheimer M.J., et al. Tumor budding with and without admixed inflammation: two different sides of the same coin? British Journal of Cancer. 2016; 114: 368–371. https://dx.doi.org/10.1038%2Fbjc.2015.454Koelzer V.H., Zlobec I., Berger M.D., et al. Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Archiv. 2015; 466:485-493. https://doi.org/10.1007/s00428-015-1740-9Koelzer V.H., Zlobec I., Berger M.D., et al. Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Archiv. 2015; 466:485-493. https://doi.org/10.1007/s00428-015-1740-9Lugli A., Vlajnic T., Giger O., et al. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair deficient colorectal cancer patients. Human Pathology. 2011; 42:1833–1840. https://doi.org/10.1016/j.humpath.2011.02.010Lugli A., Vlajnic T., Giger O., et al. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair deficient colorectal cancer patients. Human Pathology. 2011; 42:1833–1840. https://doi.org/10.1016/j.humpath.2011.02.010Ueno H., Hashiguchi Y., Kajiwara Y., et al. Proposed objective criteria for ‘grade 3’ in early invasive colorectal cancer. The American Journal of Surgical Pathology. 2010; 134:312–322. https://doi.org/10.1309/AJCPMQ7I5ZTTZSOMUeno H., Hashiguchi Y., Kajiwara Y., et al. Proposed objective criteria for ‘grade 3’ in early invasive colorectal cancer. The American Journal of Surgical Pathology. 2010; 134:312–322. https://doi.org/10.1309/AJCPMQ7I5ZTTZSOMWatanabe T., Itabashi M., Shimada Y., et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. International Journal of Clinical Oncology. 2015; 20:207–239. https://doi.org/10.1007/s10147-015-0801-zWatanabe T., Itabashi M., Shimada Y., et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. International Journal of Clinical Oncology. 2015; 20:207–239. https://doi.org/10.1007/s10147-015-0801-zLugli A., Karamitopoulos E., Zlobec I. Tumor budding: a promising parameter in colorectal cancer. British Journal of Cancer. 2012; 106:1713–1717. https://doi.org/10.1038/bjc.2012.127Lugli A., Karamitopoulos E., Zlobec I. Tumor budding: a promising parameter in colorectal cancer. British Journal of Cancer. 2012; 106:1713–1717. https://doi.org/10.1038/bjc.2012.127Kai K., Aishima S., Aoki S., et al. Cytokeratin immunohistochemistry improves interobserver variability between unskilled pathologists in the evaluation of tumor buddingin T1 colorectal cancer. Pathology International. 2016; 66:75–82 https://doi.org/10.1111/pin.12374Kai K., Aishima S., Aoki S., et al. Cytokeratin immunohistochemistry improves interobserver variability between unskilled pathologists in the evaluation of tumor buddingin T1 colorectal cancer. Pathology International. 2016; 66:75–82 https://doi.org/10.1111/pin.12374Graham R.P., Vierkant R.A., Tillmans L.S., et al. Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cut off in a population-based сohort. The American Journal of Surgical Pathology. 2015; 39:1340–1346. https://doi.org/10.1097/PAS.0000000000000504Graham R.P., Vierkant R.A., Tillmans L.S., et al. Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cut off in a population-based сohort. The American Journal of Surgical Pathology. 2015; 39:1340–1346. https://doi.org/10.1097/PAS.0000000000000504Lugli A., Karamitopoulou E., Zlobec I. Tumour budding: a promising parameter in colorectal cancer. British Journal of Cancer. 2012; 106:1713–1717. https://dx.doi.org/10.1038%2Fbjc.2012.127Lugli A., Karamitopoulou E., Zlobec I. Tumour budding: a promising parameter in colorectal cancer. British Journal of Cancer. 2012; 106:1713–1717. https://dx.doi.org/10.1038%2Fbjc.2012.127Tomita S., Yamauchi M., Ichikawa K., et al. The brand new trend of colorectal carcinoma pathology. Japanese Journal of Clinical Medicine. 2014; 72:63–70.Tomita S., Yamauchi M., Ichikawa K., et al. The brand new trend of colorectal carcinoma pathology. Japanese Journal of Clinical Medicine. 2014; 72:63–70.Kaneko I., Tanaka S., Oka S., et al. Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer. World Journal of Gastroenterology. 2007; 13:3829–3835. https://dx.doi.org/10.3748%2Fwjg.v13.i28.3829Kaneko I., Tanaka S., Oka S., et al. Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer. World Journal of Gastroenterology. 2007; 13:3829–3835. https://dx.doi.org/10.3748%2Fwjg.v13.i28.3829Nakadoi K., Tanaka S., Kanao H., et al. Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection. Journal of Gastroenterology and Hepatology. 2012; 27:1057–1062. https://doi.org/10.1111/j.1440-1746.2011.07041.xNakadoi K., Tanaka S., Kanao H., et al. Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection. Journal of Gastroenterology and Hepatology. 2012; 27:1057–1062. https://doi.org/10.1111/j.1440-1746.2011.07041.xMiyachi H., Kudo S.E., Ichimasa K., et al. Management of T1 colorectal cancers after endoscopic treatment based on the risk stratification of lymph node metastasis. Journal of Gastroenterology and Hepatology. 2016; 31:1126–1132. https://doi.org/10.1111/jgh.13257Miyachi H., Kudo S.E., Ichimasa K., et al. Management of T1 colorectal cancers after endoscopic treatment based on the risk stratification of lymph node metastasis. Journal of Gastroenterology and Hepatology. 2016; 31:1126–1132. https://doi.org/10.1111/jgh.13257Nishida T., Egashira Y., Akutagawa H., et al. Predictors of lymph node metastasis in T1 colorectal carcinoma: an immunophenotypic analysis of 265 patients. Disease of the Colon and Rectum. 2014; 57:905–915. https://doi.org/10.1097/DCR.0000000000000168Nishida T., Egashira Y., Akutagawa H., et al. Predictors of lymph node metastasis in T1 colorectal carcinoma: an immunophenotypic analysis of 265 patients. Disease of the Colon and Rectum. 2014; 57:905–915. https://doi.org/10.1097/DCR.0000000000000168Okamura T., Shimada Y., Nogami H., et al. Tumor budding detection by immunohistochemical staining is not superior to hematoxylin and eosin staining for predicting lymph node metastasis in pT1 colorectal cancer. Disease of the Colon and Rectum. 2016; 59:396–402. https://doi.org/10.1097/DCR.0000000000000567Okamura T., Shimada Y., Nogami H., et al. Tumor budding detection by immunohistochemical staining is not superior to hematoxylin and eosin staining for predicting lymph node metastasis in pT1 colorectal cancer. Disease of the Colon and Rectum. 2016; 59:396–402. https://doi.org/10.1097/DCR.0000000000000567Pai R.K., Chen Y., Jakubowski M.A., et al. Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis. Modern Pathology. 2017; 30:113–122. https://doi.org/10.1038/modpathol.2016.166Pai R.K., Chen Y., Jakubowski M.A., et al. Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis. Modern Pathology. 2017; 30:113–122. https://doi.org/10.1038/modpathol.2016.166Petrelli F., Pezzica E., Cabiddu M., et al. Tumor budding and survival in stage II colorectal cancer: a systematic review and pooled analysis. Journal of Gastrointestinal Cancer. 2015; 46:212–218. https://doi.org/10.1007/s12029-015-9716-1Petrelli F., Pezzica E., Cabiddu M., et al. Tumor budding and survival in stage II colorectal cancer: a systematic review and pooled analysis. Journal of Gastrointestinal Cancer. 2015; 46:212–218. https://doi.org/10.1007/s12029-015-9716-1Choi J.Y., Jung S.A., Shim K.N., et al. Meta-analysis of predictive clinicopathologic factors for lymph node metastasis in patients with early colorectal carcinoma. Journal of Korean Medical Science. 2015; 30:398–406. https://dx.doi.org/10.3346%2Fjkms.2015.30.4.398Choi J.Y., Jung S.A., Shim K.N., et al. Meta-analysis of predictive clinicopathologic factors for lymph node metastasis in patients with early colorectal carcinoma. Journal of Korean Medical Science. 2015; 30:398–406. https://dx.doi.org/10.3346%2Fjkms.2015.30.4.398Di Gregorio C., Bonetti L.R., de Gaetani C., et al. Clinical outcome of low- and high-risk malignant colorectal polyps: results of a population-based study and meta-analysis of the available literature. Internnal and Emergency Medicine. 2014; 9:151–160. https://doi.org/10.1007/s11739-012-0772-2Di Gregorio C., Bonetti L.R., de Gaetani C., et al. Clinical outcome of low- and high-risk malignant colorectal polyps: results of a population-based study and meta-analysis of the available literature. Internnal and Emergency Medicine. 2014; 9:151–160. https://doi.org/10.1007/s11739-012-0772-2Glasgow S.C., Bleier J.I., Burgart L.J., et al. Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases. Journal of Gastrointestinal Surgery. 2012; 16:1019–1028.Glasgow S.C., Bleier J.I., Burgart L.J., et al. Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases. Journal of Gastrointestinal Surgery. 2012; 16:1019–1028.Mou S., Soetikno R., Shimoda T., et al. Pathologic predictive factors for lymph node metastasis in submucosal invasive (T1) colorectal cancer: a systematic review and meta-analysis. Surgical Endoscopy. 2013; 27:2692–2703. https://doi.org/10.1007/s00464-013-2Mou S., Soetikno R., Shimoda T., et al. Pathologic predictive factors for lymph node metastasis in submucosal invasive (T1) colorectal cancer: a systematic review and meta-analysis. Surgical Endoscopy. 2013; 27:2692–2703. https://doi.org/10.1007/s00464-013-2

The authors declare that there are no conflicts of interest present.